Pancreatic Cancer Research

ResearcherStony Brook UniversityActive in the last 2 years

Gerardo Guillermo Mackenzie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6460-7165; OpenAlex author ID A5079097444; NIH RePORTER profile ID 9815313. Sources: OpenAlex.

Their work

Papers
20 (first author 5, last author 12)
Trials
0
Grants
7
Labs led
2
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper, 3 grants · 2017: 1 paper · 2018: 2 papers, 1 grant · 2019: 3 papers · 2020: 1 paper, 1 grant · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers, 1 grant · 2024: none · 2025: 2 papers · 2026: 1 paper, 1 grant

Papers 20

  1. Timing-Dependent Effects of ω-3 Fatty Acids on Adipose Tissue and Tumorigenesis in Obesity-Driven Pancreatic Cancer in Mice. Last author DOI 10.1016/j.tjnut.2025.101286↗
  2. Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.drudis.2025.104528↗
  3. Select bioavailable metabolites from Lippia citriodora and Olea europaea extracts exhibit anticancer effects on pancreatic cancer cell lines. Last author DOI 10.1039/d5fo02688a↗
  4. A Ketogenic Diet in Combination with Gemcitabine Mitigates Pancreatic Cancer-Associated Cachexia in Male and Female KPC Mice. Last author DOI 10.3390/ijms241310753↗
  5. Hepatic safety profile of pancreatic cancer‑bearing mice fed a ketogenic diet in combination with gemcitabine. Last author DOI 10.3892/ol.2023.14067↗
  6. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination… Last author DOI 10.1016/j.neo.2021.12.004↗
  7. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice. Last author DOI 10.1158/2767-9764.crc-22-0256↗
  8. Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice. Last author DOI 10.1158/2767-9764.crc-22-0510↗
  9. Hyaluronic acid nanoparticle-encapsulated microRNA-125b repolarizes tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.2217/nnm-2021-0080↗
  10. Ketogenic Diets in Pancreatic Cancer and Associated Cachexia: Cellular Mechanisms and Clinical Perspectives. First author DOI 10.3390/nu13093202↗
  11. Combination of miR‑143 and miR‑506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclin‑dependent kinases. First author DOI 10.3892/or.2021.7953↗
  12. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcit… Last author DOI 10.1093/carcin/bgz170↗
  13. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. First author DOI 10.1158/1535-7163.mct-18-1046↗
  14. Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. Last author DOI 10.3390/cancers11101496↗
  15. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial… Last author DOI 10.3390/nu11081856↗
  16. Pancreatic cancer: A critical review of dietary risk. First author DOI 10.1016/j.nutres.2017.12.001↗
  17. [Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glyco… Last author DOI 10.3892/ijo.2018.4584↗
  18. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticl… Last author DOI 10.3892/ijo.2017.4103↗
  19. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. First author DOI 10.2174/1574892811666160729094415↗
  20. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. Co-author DOI 10.1371/journal.pone.0061532↗

Grants 7

  1. TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer R01CA269233↗
  2. A novel small molecule targeting protein translation for pancreatic cancer treatment R21CA273506↗
  3. Phospholipase D1 and pancreatic cancer R21CA227416↗
  4. Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors R21CA213114↗
  5. A novel combination approach for pancreatic cancer prevention R03CA181727↗
  6. Pancreatic cancer control by a novel combination treatment R21CA175699↗
  7. Two phospho-compounds for pancreatic cancer prevention R21CA185209↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mansoor M. Amiji · 3 shared papers, 2 shared grants, 2018–2026 · strength 1.86
  2. Natalia E. Cortez · 5 shared papers, 2021–2023 · strength 0.96
  3. Cecilia Rodríguez Lanzi · 5 shared papers, 2022–2023 · strength 0.90
  4. James E Egan · 1 shared grant, 2026 · strength 0.86
  5. Edward J Kim · 1 shared grant, 2026 · strength 0.86
  6. Ruiwu Liu · 1 shared grant, 2023 · strength 0.77
  7. Ran Wei · 4 shared papers, 2019–2022 · strength 0.61
  8. George Mattheolabakis · 4 shared papers, 2013–2021 · strength 0.48
  9. Basil Rigas · 4 shared papers, 2013–2020 · strength 0.38
  10. Dingyuan Luo · 2 shared papers, 2020–2022 · strength 0.35
  11. Satveer Jagwani · 1 shared paper, 2025 · strength 0.33
  12. Aya Ead · 1 shared paper, 2026 · strength 0.32
  13. María del Carmen Villegas-Aguilar · 1 shared paper, 2025 · strength 0.28
  14. Jihao Xu · 2 shared papers, 2022 · strength 0.27
  15. Chang‐Il Hwang · 2 shared papers, 2022 · strength 0.27
  16. A K M Nawshad Hossian · 1 shared paper, 2021 · strength 0.22
  17. Neha N. Parayath · 1 shared paper, 2021 · strength 0.19
  18. Asmaa A. Salem · 1 shared paper, 2018 · strength 0.17
  19. Gulzar Ahmad · 1 shared paper, 2019 · strength 0.14
  20. Daiwen Chen · 1 shared paper, 2022 · strength 0.13
  21. Joseph F. LaComb · 1 shared paper, 2020 · strength 0.13
  22. Harold Bien · 1 shared paper, 2016 · strength 0.10
  23. Minsig Choi · 1 shared paper, 2016 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.